Top

RATG: Prospective Phase II Pilot study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical patients treated with horse ATG and Ciclosporin

Study number:

2007-00902-55

Type of transplant:

Short title:

RATGAA07

Study status:

Completed Patient Recruitment

Deadline for data collection:

Study design:

Non-randomized,prospective,multi-centre, phaseII pilot study

Primary objective:

Assess tolerability and efficacy of rabbit ATG (Thymoglobuline®) with CSA in the first line treatment of patients with acquired SAA, and patients with NSAA

Key inclusion criteria:

>=16years (18 in DE + CH)

Country:

France

Germany

Italy

Saudi Arabia

Switzerland

United Kingdom

Principal investigator:

Judith Marsh

Principal investigator email:

EBMT Study coordinator:

Alain Barrois

http://www.clinicaltrials.gov/ct2/show/NCT00471848?term=RATGAA07&rank=1

Need help?

First Name

Last Name

Email address

CIC number

Area of interest

Message box

I understand and accept that my personal data will be used for communication concerning the submitted query or request.

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org